Amniotic Liquid Allograft is created with the use of cutting-edge second-generation stem cell technology. Liquid allograft is derived from the amniotic cell layer of a placenta obtained from consenting donors after delivery of a healthy, full-term, elective Cesarean birth. There is no harm to the donor mother or newborn baby.
The refined liquid allograft has 10 times the growth factors and cytokines found in the blood of an 18 year old. The natural growth factors and cytokines that are present in liquid allograft help repair and replace damaged soft-tissue while inhibiting inflammation and scar tissue formation.
Amniotic Liquid Allograft is FDA cleared and classified as minimally manipulated under FDA regulations 21 CFR part 1271 and section 361 of the PHS.
During pregnancy, every vertebrate has layers of extraembryonic tissue surrounding the developing fetus called placental membranes, or fetal membranes. The two fetal membranes which immediately surround the amniotic cavity are the chorion (outer membrane) and the amnion (inner membrane). The chorion is an opaque membrane which lies on the outer layer of the amniotic sac, whereas the amnion is a more translucent structure which lies on the inner layer, adjacent to the amniotic fluid . These membranes have a composition of extracellular connective tissue components, making them a promising biomaterial for a variety of therapies. Additionally, the cells of these fetal membranes are a potential source of material for stem cell therapies. Transmission electron microscopy (TEM) comparisons of the ultrastructure of chorion vs. amnion stromal cells show that chorion stromal cells are similar to hematopoietic progenitor cells, while amnion stromal cells are more like mesenchymal and epithelial cells, suggesting multi-potentiality . Due to the composition of extracellular connective tissue components and the stem cell properties of their epithelial and mesenchymal cells, the amnion has become highly attractive